Clinical Trials
21 results for Bladder Cancer
Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
- Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
- Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
- Study ID: NCT01050504
Familial and Atypical Urothelial Cancer Registry
- Condition: Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
- Intervention: Other: saliva sample and questionaire, Other: saliva sample, questionaire
- Study ID: NCT00902590
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum
- Condition: Stage IV Bladder Urothelial Carcinoma
- Intervention: Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Procedure: Positron Emission Tomography, Biological: Recombinant EphB4-HSA Fusion Protein
- Study ID: NCT02717156
A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)
- Condition: Bladder Cancer
- Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
- Study ID: NCT03520491
Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"
- Condition: Upper Tract Urothelial Carcinoma
- Intervention: Procedure: RNU, Drug: Gemcitabine/Cisplatin, Drug: M-VAC Protocol
- Study ID: NCT02969083
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
- Condition: Urothelial Carcinoma
- Study ID: NCT03547973
A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
- Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
- Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
- Study ID: NCT03844256
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Co
- Condition: Urothelial Carcinoma
- Intervention: Drug: Atezolizumab, Drug: Enfortumab Vedotin, Drug: Niraparib, Drug: Hu5F9-G4, Drug: Isatuximab, Drug: Linagliptin, Drug: Tocilizumab
- Study ID: NCT03869190
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY
- Condition: Urinary Bladder Neoplasms
- Intervention: Drug: Pembrolizumab, Radiation: Conventional Radiotherapy (Bladder only), Radiation: Conventional Radiotherapy (Bladder and pelvic nodes), Radiation: Hypofractionated Radiotherapy (Bladder only), Drug: Cisplatin, Drug: Fluorouracil (5-FU), Drug: Mitomycin C (MMC), Drug: Gemcitabine, Drug: Placebo to Pembrolizumab
- Study ID: NCT04241185
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
- Condition: Bladder Cancer, Bladder Cancer, Metastatic
- Intervention: Drug: Atezolizumab
- Study ID: NCT04138628
Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
- Condition: Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
- Study ID: NCT04936230
A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
- Condition: Muscle-invasive Bladder Cancer
- Study ID: NCT04660344
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
- Condition: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Study ID: NCT05987241
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial
- Condition: Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
- Study ID: NCT06257017
Carboplatin-gemcitabine Versus Cisplatin-gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer: a Prospective Randomized Trial
- Condition: Urinary Bladder Cancer
- Study ID: NCT05822934
Patient Preferences of Treatment for the Patients Suffering From Muscle-invasive Urothelial Carcinoma of Bladder Following Radical Cystectomy in Japan
- Condition: Urinary Bladder Neoplasms
- Study ID: NCT05742867
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cyste
- Condition: Urinary Bladder Neoplasms
- Study ID: NCT04658862
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for o
- Condition: Urinary Bladder Neoplasms
- Study ID: NCT04919512
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
- Condition: Ovarian Epithelial Cancer, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Triple Negative Breast Cancer, Bladder Cancer
- Intervention: Drug: SKB264
- Study ID: NCT04152499
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients With MIBC (RAD-SG).
- Condition: Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
- Study ID: NCT05833867
Understanding Tumor and Immune Dynamics and Predicting Response to Various Perioperative Therapies in Patients With Muscle-invasive Bladder Cancer
- Condition: Bladder Cancer
- Study ID: NCT06341478